☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - June 2018

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Fluticasone / Formoterol (Flutiform k-haler®) has been accepted for use in the regular treatment of asthma where the use of a combination product is an appropriate treatment. This inhaler is a breath-actuated inhaler that is bioequivalent to Flutiform metered-dose inhaler (pMDI) and costs the same.

Eslicarbazepine (Zebinix®) has been rejected for use as monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. The manufacturer failed to make a submission for this indication.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - June 2018' by emailShare 'SMC Update - June 2018' on FacebookShare 'SMC Update - June 2018' on TwitterShare 'SMC Update - June 2018' on LinkedInShare 'SMC Update - June 2018' on reddit

atomic-wealth

No Comments to “SMC Update - June 2018”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.

vipers